

A

07/27/99

35674 U.S. PTO

09362021 072799

UTILITY PATENT APPLICATION TRANSMITTAL (Only for new nonprovisional applications under 37 CFR 1.53(b))		Attorney Docket No.: D/96602		Total Pages:	
		First Named Inventor or Application Identifier			
		Robert J. Meyer et al.			
		Express Mail Label No.:		EL002145303US	

APPLICATION ELEMENTS See MPEP Chapter 600 concerning utility patent application contents.	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
--	---

<p>1. <input checked="" type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)</p> <p>2. <input checked="" type="checkbox"/> Specification (incl. claims) (Total Pages: 24)</p> <p>3. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) (Total Sheets: 10) <input type="checkbox"/> Informal <input checked="" type="checkbox"/> Formal</p> <p>4. <input checked="" type="checkbox"/> Oath or Declaration (Total Pages: 2) a. <input type="checkbox"/> Newly executed <input checked="" type="checkbox"/> Unexecuted (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17 completed) (Note Box 5 below) <input type="checkbox"/> i. DELETION OF INVENTOR(S) Signed statement attached deleting Inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</p> <p>5. <input type="checkbox"/> Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.</p>	<p>6. <input type="checkbox"/> Microfiche Computer Program (Appendix)</p> <p>7. Nucleotide and/or Amino Acid Sequence Submission (If applicable, all necessary) a. <input type="checkbox"/> Computer Readable Copy b. <input type="checkbox"/> Paper Copy (Identical to computer copy) c. <input type="checkbox"/> Statement verifying identity of above copies</p>
---	---

ACCOMPANYING APPLICATION PARTS
<p>8. <input checked="" type="checkbox"/> Assignment Papers (cover sheet & document(s))</p> <p>9. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input checked="" type="checkbox"/> Power of Attorney (when there is an assignee)</p> <p>10. <input type="checkbox"/> English Translation Document (if applicable)</p> <p>11. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input checked="" type="checkbox"/> Copies of IDS Citations</p> <p>12. <input type="checkbox"/> Preliminary Amendment</p> <p>13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)</p> <p>14. <input type="checkbox"/> Small Entity Statement(s) <input type="checkbox"/> Statement filed in prior application, Status still proper and desired</p> <p>15. <input type="checkbox"/> Certified Copy of Priority Document(s) (If foreign priority is claimed)</p> <p>16. <input type="checkbox"/> Other:</p>

17. ☐ If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information:
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: /

18. CORRESPONDENCE ADDRESS

☐ Same as prior application ☒ Correspondence address below

NAME	John E. Beck				
ADDRESS	Xerox Corporation, Xerox Square - 20A				
CITY	Rochester	STATE	NY	ZIP CODE	14644
COUNTRY	U.S.A.	TELEPHONE	716-423-6918	FAX	716-423-5240 or 716-423-2750

35674 U.S. PTO

09/16/2021

07/27/99

Attorney Docket No. D/96602

19. ☐ Cancel in this application original claims: _____ of the prior application before calculating the filing fee.
(At least one original independent claim is retained for this filing).

20. ☒ The filing fee is calculated below:


CLAIMS AS FILED, LESS ANY CLAIMS CANCELED BY ABOVE-INDICATED AMENDMENT(S)				
(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
TOTAL CLAIMS (37 CFR 1.16(c))	22 - 20 =	2	x \$ 18	= \$36.00
INDEPENDENT CLAIMS (37 CFR 1.16(b))	3 - 3 =	0	x \$ 78	= \$0.00
MULTIPLE DEPENDENT CLAIMS (IF APPLICABLE) (37 CFR 1.16(d))		ANY - - 0	\$ 260	= \$0.00
BASIC FEE (37 CFR 1.16(a))				\$760.00
TOTAL				= \$ 796.00

21. ☒ The Commissioner is hereby authorized to charge any filing or prosecution fees which may be required, under 37 CFR 1.16, 1.17, and 1.21 (but not 1.18), or to credit any overpayment, to Account No. 24-0025.
An additional copy of this form is enclosed.
22. ☒ This is an authorization under 37 CFR 1.136(a)(3) to treat any concurrent or future reply, requiring a petition for extension of time, as incorporating a petition for the appropriate extension of time.
23. ☐ Amend the specification by inserting before the first line the sentence:
--This application is a ☐ continuation ☐ continuation-in-part ☐ divisional
of Application(s) No(s) _____, filed _____.
24. ☐ A CIP declaration is enclosed.
25. ☐ Power of Attorney
- a. ☐ The power of attorney appears in the original papers of the enclosed prior application.
- b. ☐ Enclosed is a copy of the declaration and power of attorney from the enclosed prior application.
- c. ☐ A new declaration with power of attorney is enclosed.

Attorney Docket No.: D/96602

26. ☐ The following inventors named in the prior application are deleted per 37 CFR 1.53(b)(1), 1.63(d)(2) and 1.33 (b):
27. ☐ This application is adding one or more inventors under 37 CFR 1.48 to a previously executed application, with an enclosed: petition, fee, newly executed declaration from all inventors, and written consent of the assignee.
28. ☐ This application claims the priority benefit of one or more Provisional Application No(s). and the first sentence of this application has been or will be amended to so indicate.
29. ☐ Priority is claimed from (reinsert all previous priority claims for the entire chain of any prior applications).
30. ☐ Other paper(s) enclosed:

Respectfully submitted,



Christopher D. Wait

Signature per 37 CFR 1.33 & 34

Date: 7/27/1999

Registration No. 43,230

Telephone No. 716-423-6918

09362021-072799